Kiniksa(KNSA) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution – ARCALYST (rilonacept) Q3 2024 net product revenue of $112.2 million, representing 73% year-over-year growth – – ARCALYST 2024 expected net product revenue increased to$ 410 - $420 million – – Life DisRPted disease awareness campaign for recurrent pericarditis launched in partnership with NHL Hall of Famer, Henrik Lundqvist, and GRAMMYAward-winning singer-songwriter, Carly Pearce – – Kiniksa exp ...